A Lancet Neurology review found robust RCT evidence supporting CBD for Lennox-Gastaut and Dravet syndromes, approved treatments for MS pain and spasticity, but no effect found in trials for Huntington's, ADHD, or dementia.
People interested in evidence-based cannabinoid medicine, neurological disorders, and the gap between cannabis hype and proven benefit.
Strong evidence for epilepsy and MS; no effect found for Huntington's, ADHD, or dementia
What the researchers found
Randomized controlled trials provide evidence of CBD's anti-seizure effects for Lennox-Gastaut and Dravet syndromes. Cannabis-based treatments for MS pain and spasticity are approved in some countries. However, small clinical trials found no effects for Huntington's disease, ADHD, or dementia.
Why it matters
Published in a top-tier neurology journal, this review provides a reality check on cannabinoid therapeutics. While epilepsy and MS have genuine evidence, the enthusiasm around cannabis for neurological conditions generally outpaces the science.
The numbers in context
CBD approved for Lennox-Gastaut and Dravet syndromes based on RCTs. Cannabis-based treatments for MS pain and spasticity approved in some countries. No effect found in small trials for Huntington's disease, ADHD, and dementia.
How the study worked
Narrative review published in The Lancet Neurology examining the evidence for cannabinoids across neurological disorders including epilepsy, multiple sclerosis, pain, and neurodegenerative diseases, focusing on randomized controlled trial data.
What this study cannot tell us
Narrative review format. Negative findings for conditions like ADHD and dementia may reflect underpowered studies rather than true absence of effect. Mechanisms of cannabinoid action remain incompletely understood.
How to read the evidence
Strong: published in The Lancet Neurology, synthesizing RCT evidence across multiple neurological conditions.
When this study was published
Published in 2019.
The bigger picture
The pattern is clear: where large, well-designed RCTs have been conducted (severe pediatric epilepsy), CBD shows real benefit. Where only small trials exist (ADHD, dementia), no effects have been found. This suggests the field needs more rigorous trials, not more anecdotes.
Questions still open
- Could larger, better-designed trials find cannabinoid effects in ADHD or dementia? Do CBD's anti-seizure effects extend beyond Dravet and Lennox-Gastaut to other epilepsies? What are the long-term effects of cannabinoid treatments for neurological conditions?
Common questions
Which neurological conditions does cannabis actually help?
Why doesn't cannabis work for all brain conditions?
Read the original research
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.
The Lancet. Neurology, 18(5), 504-512
Citation
Friedman, Daniel; French, Jacqueline A; Maccarrone, Mauro. (2019). Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.. The Lancet. Neurology, 18(5), 504-512. https://doi.org/10.1016/S1474-4422(19)30032-8
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk